National Bank of Canada FI Sells 98,755 Shares of IQVIA Holdings Inc. (NYSE:IQV)

National Bank of Canada FI lessened its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 54.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 82,668 shares of the medical research company's stock after selling 98,755 shares during the quarter. National Bank of Canada FI's holdings in IQVIA were worth $16,245,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Smith Group Asset Management LLC bought a new stake in IQVIA during the 4th quarter valued at approximately $1,616,000. Nordea Investment Management AB grew its stake in shares of IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock worth $277,908,000 after acquiring an additional 452,029 shares during the last quarter. Hickory Asset Management Inc. bought a new position in IQVIA during the fourth quarter worth $941,000. Fifth Third Bancorp boosted its holdings in IQVIA by 13.0% in the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company's stock valued at $2,590,000 after purchasing an additional 1,521 shares during the period. Finally, Graphene Investments SAS grew its position in IQVIA by 22.0% in the 4th quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company's stock worth $2,948,000 after purchasing an additional 2,700 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Trading Down 9.8 %

IQVIA stock traded down $15.46 during mid-day trading on Thursday, hitting $141.56. The stock had a trading volume of 790,419 shares, compared to its average volume of 1,618,600. The stock has a market capitalization of $24.96 billion, a PE ratio of 18.88, a P/E/G ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a 12 month low of $135.97 and a 12 month high of $252.88. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a 50-day simple moving average of $184.54 and a two-hundred day simple moving average of $200.91.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on IQV shares. William Blair reiterated an "outperform" rating on shares of IQVIA in a research note on Wednesday, December 11th. JPMorgan Chase & Co. cut their target price on IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research note on Tuesday, February 18th. Robert W. Baird lowered their price target on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a report on Tuesday, January 21st. UBS Group reduced their price objective on shares of IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a report on Friday, February 7th. Finally, StockNews.com cut shares of IQVIA from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th. Six analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, IQVIA currently has an average rating of "Moderate Buy" and an average price target of $241.50.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.